PubMed Health⌕ Search

Biomedical subjects

A Gabbai

Publications and source records attributed to A Gabbai.

12 recordsLinked to original sources
PubMed1987

Breathing pattern during exercise in myopathic subjects.

Previous studies have described a neurogenic-induced ventilatory tachypneic response during exercise. The present paper compares the breathing pattern of control and myopathic human subjects submitted to exercise. Peripheral neurogenic stimuli (PNS) at the same level of oxygen consumption should be enhanced in myopathic subjects as a consequence of muscular mass loss. Myopathic individuals showed hyperventilation (increased VeO2 and VeCO2) which was mostly due to higher respiratory frequency. The shorter respiratory cycle was due chiefly to Te reduction, since the Ti/TTOT ratio was greater in the myopathic individuals for a VO2 of 1 L. These results are in agreement with previous studies in anesthetized dogs and in unanesthetized humans in which a tachypneic mechanism associated to the relative work load was observed. These results also suggest that PNS may have a facilitatory effect upon the inspiratory off switch mechanism.

Adolescent↗
PubMed1987

Cardiorespiratory responses to exercise in patients with spinal muscular atrophy and limb-girdle dystrophy.

Maximum oxygen consumption, maximum heart rate and maximum ventilation during cycle ergometer exercise were studied in individuals with spinal muscular atrophy (N = 8) and limb-girdle dystrophy (N = 8). The limiting factors in aerobic power may be related to loss of functional muscular mass rather than to changes in the oxygen transport system. There was no correlation between VO2 max values and muscle strength as determined by a manual test of the affected muscles recruited for bicycle exercise. The results, therefore, do not support the possibility of a correlation between these indices previously proposed on the basis of clinical evidence.

Adolescent↗
PubMed1984

A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis.

We conducted a double-blind controlled study of the effect of brain gangliosides in amyotrophic lateral sclerosis. Nineteen patients received intramuscular gangliosides (40 mg/d) for 6 months, and 21 received placebo. The deterioration rates for approximately 120 clinical and electrophysiologic parameters of neuromuscular function were analyzed, but no statistically significant beneficial effect of the drug was demonstrated. However, the large coefficient of variation for each item indicated that a sample size of several hundred patients would have been necessary to exclude the possibility that the drug produced a 25% slowing of progression of the disease.

Amyotrophic Lateral Sclerosis↗
PubMed1982

[Acro-osteolysis in leprosy. Apropos of 19 personal cases].

Using their own personal series of 19 cases of leprosy complicated by massive osteolysis (AO), along with a comparison of these cases with data from previously published reports, the authors review the principal clinical and radiological findings of these manifestations which are not observed except in cases of leprosy where neuropathy is present, even though other factors (perforating plantar ulcers, poor hygiene, traumatisms) may play a contributing role independent of possible interference from non specific osteoarthritis or Hansen's bacilla, itself. After reviewing other causes of massive osteolysis and discussing the pathogeny of these manifestations during leprosy, the authors refer to the various therapies which can prevent or stabilize osteolysis or aid the patient to better tolerate its manifestations.

Adolescent↗
PubMedDate not supplied

[The treatment of multiple sclerosis in Latin America: current practice and optimal standards. The findings of a survey among neurologists at an interactive workshop].

INTRODUCTION: Considerable progress has been made in the treatment of patients with relapsing-remitting multiple sclerosis (MS) over the last decade. Exactly how these changes are reflected in daily practice, however, is still not very well known. AIM: To hold interactive workshops so as to be able to evaluate the opinions of Latin-American neurologists about the therapeutic decisions taken with regard to MS. MATERIALS AND METHODS: By means of an interactive voting system, professionals attending each workshop replied to ten pre-established questions about when to start treatment, the use of magnetic resonance imaging (MRI) to supervise treatment, the definition of therapeutic failure and the role of treatment using immunosuppressants. The results were compared with those obtained in similar workshops attended by European and North American neurologists held six months earlier. RESULTS: The use of immunomodulators was considered to be useful in isolated demyelinating syndromes, as 40-50% endorsed their use in clinically stable patients. MRI was seen to be the most sensitive method of monitoring the effectiveness of the therapy -70.6% of them proposed the application of annual scans, which suggests a more frequent use in Latin America than in Europe or the USA. On defining therapeutic failure, the clinical criteria were more important than the MRI scan, and a switch from beta interferons to glatiramer acetate or vice versa was recommended. Treatment with immunosuppressants was considered to be useful in reducing the accumulated disability, but there was no agreement on how to use them. In Latin America, decisions about when to begin treatment seem to lie somewhere between the more favourable posture adopted in USA and the more conservative stance in Europe. CONCLUSIONS: This survey reflects the controversies that affect the therapeutic decisions concerning MS in Latin America and highlights the areas in which more data are needed to optimise the standards of treatment.

Consensus Statements as Topic↗
PubMedDate not supplied

Growth of transplanted tumours in mice treated with macrophages and their products.

The antitumour activity of peritoneal macrophages, added to tumour inocula (Winn test), was determined. Macrophages harvested from mice immunised with tumour, or from tumour-bearing mice, suppressed or inhibited tumour growth when in direct contact with tumour cells. Incubation of macrophages exhibiting antitumour activity with tumour cells yielded supernatant fluids capable of interfering with tumour growth. Consistent induction of antitumor activity required either addition of indomethacin to the incubation mixture, or collection of macrophages from immunised or tumour-bearing donors that had ingested indomethacin in the drinking water. Tumour growth was significantly inhibited when tumour inocula were suspended in supernatant fluid, or when mice were given several subcutaneous injections of supernatant prior to tumour transplantation.

Adjuvants, Immunologic↗